Asilian 20212222 Asilian A, Safaei H, Iraji F, Fatemi Naeini F, Faghihi G, Mokhtari F. Interventions for bullous pemphigoid: An updated systematic review of randomized clinical trials. Med J Islam Repub Iran. 2021;35:111.
|
3 |
Bullous pemphigoid |
Methylprednisolone |
Mortality |
No funding sources reported. |
Azathioprine |
Disease control |
Dapsone |
Adverse Events |
Doxycycline |
Time to complete response |
Prednisolone |
Intravenous immunoglobulin |
Atzmony 20142323 Atzmony L, Hodak E, Gdalevich M, Rosenbaum O, Mimouni D. Treatment of pemphigus vulgaris and pemphigus foliaceus: a systematic review and meta-analysis. Am J Clin Dermatol. 2014;15:503-15.
|
20 |
Pemphigus vulgaris, pemphigus foliaceus |
Azathioprine |
Complete response |
No funding sources reported. |
Mycophenolate mofetil |
Mean total cumulative glucocorticoid dose |
Cyclophosphamide |
Intravenous immunoglobulin |
Mortality |
Disease control |
Remission |
Relapse |
Withdrawal due to adverse events |
Atzmony 20152424 Atzmony L, Hodak E, Leshem YA, Rosenbaum O, Gdalevich M, Anhalt GJ, et al. The role of adjuvant therapy in pemphigus: A systematic review and meta-analysis. J Am Acad Dermatol. 2015;73:264-71.
|
10 |
Pemphigus vulgaris, pemphigus foliaceus |
Glucocorticoid |
Remission |
No funding sources reported. |
Azathioprine |
Disease control |
Mycophenolate mofetil |
Relapse |
Cyclophosphamide |
Cumulative glucocorticoid dose |
Cyclosporine |
Withdrawal due to adverse events |
Intravenous immunoglobulin plasma exchange |
Mortality |
Infliximab |
Kirtschig 20102525 Kirtschig G, Middleton P, Bennett C, Murrell DF, Wojnarowska F, Khumalo NP. Interventions for bullous pemphigoid. Cochrane Database Syst Rev. 2010;CD002292.
|
10 |
Bullous pemphigoid |
Prednisolone |
Disease control |
No funding sources reported. |
Azathioprine |
Mortality |
Plasma exchange |
Overall improvement |
Mycophenolate mofetil, tetracycline |
Several adverse events |
Nicotinamide |
Quality of life |
Chinese traditional medicine |
Remission |
Systemic infection |
Organ failure |
Allergic reactions |
Garcia-Doval 20132626 Garcia-Doval I, Davila-Seijo P, Langan SM. Updated systematic review of randomized controlled trials of treatments for inherited forms of epidermolysis bullosa. Clin Exp Dermatol. 2013;38:92-4.
|
7 |
Inherited forms of epidermolysis bullosa |
Tetracyclines |
Overall improvement |
No funding sources reported. |
Oxytetracycline |
Prevention of new lesions |
Aluminium chloride hexahydrate solution |
Pain and pruritus |
Quality of life |
Bufexamac cream |
Expression of COL7A1 mRNA, type 7 collage |
Phenytoin |
Anchoring fibrils |
Cultured allogeneic fibroblasts |
Number and characteristics of lesions |
Trimethoprim |
Patient perception |
Number of infection |
Emergence of resistant bacteria |
Majumdar 20022727 Majumdar S, Mockenhaupt M, Roujeau J, Townshend A. Interventions for toxic epidermal necrolysis. Cochrane Database Syst Rev. 2002;CD001435.
|
1 |
Toxic epidermal necrolysis |
Thalidomide |
Mortality |
No funding sources reported. |
Quality of life |
Pain during acute episode |
Loss of total body surface area |
Serious infection |
Renal failure |
Length of hospital stay |
Bone marrow toxicity |
Martin 20092828 Martin LK, Werth V, Villanueva E, Segall J, Murrell DF. Interventions for pemphigus vulgaris and pemphigus foliaceus. Cochrane Database Syst Rev. 2009;CD006263.
|
11 |
Pemphigus vulgaris and pemphigus foliaceus |
Prednisolone |
Remission |
No funding sources reported. |
Dexamethasone |
Mortality |
Azathioprine |
Disease control |
Cyclophosphamide |
Relapse |
Cyclosporine |
Change in pemphigus severity score |
Dapsone |
Mycophenolate |
Time to disease control |
Plasma exchange |
Cumulative glucocorticoid dose |
Topical epidermal growth factor |
Reduction of serum antibody titres |
Traditional Chinese medicine |
Adverse events |
Quality of life |
Singh 20112929 Singh S. Evidence-based treatments for pemphigus vulgaris, pemphigus foliaceus, and bullous pemphigoid: a systematic review. Indian J Dermatol Venereol Leprol. 2011;77:456-69.
|
19 |
Pemphigus vulgaris, pemphigus foliaceus, and bullous pemphigoid |
Prednisolone |
Adverse Events |
No funding sources reported. |
Methylprednisolone |
Overall improvement |
Dexamethasone |
Remission |
Cyclophosphamide |
Dapsone |
Intravenous immunoglobulin |
Mycophenolate mofetil |
Cyclosporine |
Azathioprine |
Zhao 20153030 Zhao CY, Murrell DF. Pemphigus vulgaris: an evidence-based treatment update. Drugs. 2015;75;271-84.
|
18 |
Pemphigus vulgaris |
Mycophenolate mofetil |
Mortality |
No funding sources reported. |
Azathioprine |
Disease control |
Intravenous immunoglobulins |
Relapse |
Sulfasalazine |
Withdrawal due to adverse events |
Pentoxifylline |
Infliximab |
Epidermal growth factor |
Pimecrolimus |